hydroxyurea has been researched along with Aortitis in 1 studies
Aortitis: Inflammation of the wall of the AORTA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gaztanaga, J | 1 |
| Farkouh, M | 1 |
| Rudd, JH | 1 |
| Brotz, TM | 1 |
| Rosenbaum, D | 1 |
| Mani, V | 1 |
| Kerwin, TC | 1 |
| Taub, R | 1 |
| Tardif, JC | 1 |
| Tawakol, A | 1 |
| Fayad, ZA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event[NCT00552188] | Phase 2 | 52 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluate the effect of VIA-2291 100 mg relative to placebo on the change from baseline in the target (plaque) to background (blood) ratio (TBR) from an index vessel (either right carotid, left carotid or ascending aorta) based on the standardized 18fluorodeoxy glucose (FDG) uptake measured with PET in patients with acute coronary syndrome and vascular inflammation after 24 weeks of daily dosing. (NCT00552188)
Timeframe: Baseline and 24 Weeks
| Intervention | TBR (Least Squares Mean) |
|---|---|
| VIA-2291 | -0.01 |
| Placebo | -0.06 |
To evaluate the effect of VIA-2291 100 mg relative to placebo on the change from baseline in the TBR from an index vessel (either right carotid, left carotid or ascending aorta) based on the standardized 18FDG uptake measured with PET in patients after 6 weeks of daily dosing. (NCT00552188)
Timeframe: Baseline and 6 Weeks
| Intervention | TBR (Least Squares Mean) |
|---|---|
| VIA-2291 | 0.01 |
| Placebo | -0.07 |
1 trial available for hydroxyurea and Aortitis
| Article | Year |
|---|---|
A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aortitis; Aortography; Canada; Carotid Artery Diseases; Double-Blind | 2015 |